Myriad Genetics Inc MYGN.OQ MYGN.O is expected to show a fall in quarterly revenue when it reports results on February 23 for the period ending December 31 2025
The Salt Lake City Utah-based company is expected to report a 1.5% decrease in revenue to $207.366 million from $210.6 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.The company's guidance on January 12 2026, for the period ended December 31, was for revenue between $207.00 million and $209.00 million. (Sales Majority is on Total / Net Revenue basis)
LSEG's mean analyst estimate for Myriad Genetics Inc is for a loss of 1 cent per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 7 "hold" and 3 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Myriad Genetics Inc is $7.00, about 59.8% above its last closing price of $4.38
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.01 | -0.01 | 0.00 | Beat | 100 |
Jun. 30 2025 | -0.01 | -0.01 | 0.05 | Beat | 638.2 |
Mar. 31 2025 | -0.06 | -0.06 | -0.03 | Beat | 48.9 |
Dec. 31 2024 | 0.03 | 0.03 | 0.03 | Met | -1 |
Sep. 30 2024 | 0.02 | 0.02 | 0.06 | Beat | 211.4 |
Jun. 30 2024 | -0.01 | -0.01 | 0.05 | Beat | 508.8 |
Mar. 31 2024 | -0.11 | -0.10 | -0.01 | Beat | 90.5 |
Dec. 31 2023 | 0.01 | 0.01 | 0.04 | Beat | 214.2 |
This summary was machine generated February 20 at 22:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)